Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

UCB/Sanofi’s Xyzal Clears FDA As Once-Daily Antihistamine

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Xyzal will be available for the fall allergy season after being approved for symptoms associated with seasonal and perennial allergic rhinitis.

You may also be interested in...



Generic Keppra Set For Launch In November 2008 After UCB Settles

Mylan could launch generic versions of the antiepileptic Nov. 1, 2008, two months ahead of anticipated exclusivity expiry of levetiracetam.

Generic Keppra Set For Launch In November 2008 After UCB Settles

Mylan could launch generic versions of the antiepileptic Nov. 1, 2008, two months ahead of anticipated exclusivity expiry of levetiracetam.

UCB’s Next Allergy Partner Is Sanofi-Aventis

Xyzal, pending in the U.S. for allergic rhinitis treatment, could be a replacement for Allegra.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS066103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By